Citations 2
TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax
Gangat, Naseema, Warraich, Momna , Kumar, Sudhesh, Fatima, Mahnoor , Begna, Kebede H. , Al‐Kali, Aref, Patnaik, Mrinal M. , Hogan, William J., Mangaonkar, Abhishek, Torghabeh, Mehrdad Hefazi, Alkhateeb, Hassan, Shah, Mithun V., Foran, J., Palmer, Jeanne , Pardanani, Animesh, Tefferi, Ayalew, Gangat, Naseema , Mangaonkar, Abhishek A. , Saliba, Antoine N , Foran, James M , Badar, Talha , Tefferi, Ayalew , Gangat, Naseema , Kumar, Sudhesh , McCullough, Kristen , Al‐Kali, Aref , Hogan, William J. , Mangaonkar, Abhishek A. , Saliba, Antoine N. , Hefazi, Mehrdad , Alkhateeb, Hassan B. , Shah, Mithun V., Foran, James M. , Badar, Talha , Yi, Cecilia Arana , Pardanani, Animesh , Tefferi, Ayalew
American Journal of Hematology | February 19, 2026 | Volume: 101 | Issue: 4 | Pages: 866-871
Post‐ FDA Approval Experience With Momelotinib in JAK Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Perip
Tefferi, Ayalew, Abdelmagid, Maymona, Palmer, Jeanne , Al‐Kali, Aref, Yi, Cecilia Y. Arana , Matin, Aasiya, Alkhateeb, Hassan B., Badar, Talha , Bashir, Yassin, Reichard, Kaaren K. , He, Rong , Pardanani, Animesh , Gangat, Naseema, Tefferi, Ayalew , Al-Kali, Aref , Gangat, Naseema , Badar, Talha , Tefferi, Ayalew , Al‐Kali, Aref , Yi, Cecilia Arana , Matin, Aasiya , Alkhateeb, Hassan B. , Gangat, Naseema
American Journal of Hematology | January 8, 2026 | Volume: 101 | Issue: 3 | Pages: 570-576